- China introduced new import tax incentives effective January 1, 2026, covering sectors like pharmaceuticals, R&D, science outreach, energy, seeds, firefighting, and trade exhibitions, valid mostly through December 31, 2030.
- Key benefits include reduced VAT for anti-cancer and rare disease drugs, full tax exemptions for R&D and science outreach equipment, duty and VAT exemptions for offshore energy projects, and VAT exemptions for seeds and rescue animals.
- The policies lower input costs for foreign and domestic businesses in strategic sectors, supporting long-term planning and investment.
- Foreign-invested R&D centers are explicitly eligible, encouraging high-value foreign R&D activity in China.
- Eligibility is not automatic; companies must proactively register and periodically re-verify with authorities.
Source: china-briefing.com
Note that this post was (partially) written with the help of AI. It is always useful to review the original source material, and where needed to obtain (local) advice from a specialist.
Latest Posts in "China"
- China Clarifies SME Tax Preference Rules: New Tests Target Artificial Revenue Splitting and Abuse
- China Extends Import Tax Relief for Returned Cross-Border E-Commerce Goods Through 2027
- VAT Return Filing Instructions Updated to Align with New VAT Law Effective February 2026
- GAC Releases Customs Codes for Goods Under 9% Import VAT Rate Following New Regulations
- China’s PV Export Policy Shift: From Price Competition to Value, Quality, and Industry Consolidation
